FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Torben Palshof

Research Profile

Geographic Areas

Denmark

Disorders

Chemicals & Drugs

Concepts & Ideas

Activities & Behaviors

Co-author Network

Publications

TOP 3
Erik Jakobsen; Anders Green; Kell Østerlind; Torben Palshof
[Danish Lung Cancer Registry].
Louise B Hartlev; Torben Palshof; Henrik Bluhme; Charlotte R Boeje; Michael Rehling
Monitoring renal function during chemotherapy.
Niels Kroman; Torben Palshof
[The course of cancer in health care--time for a time out?].

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Torben Palshof (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Erik Jakobsen; Anders Green; Kell Østerlind; Torben Palshof
[Danish Lung Cancer Registry].
Ugeskrift for laeger 2012;174(42):2539.
2012: Louise B Hartlev; Torben Palshof; Henrik Bluhme; Charlotte R Boeje; Michael Rehling
Monitoring renal function during chemotherapy.
European journal of nuclear medicine and molecular imaging 2012;39(9):1478-82.
2011: Niels Kroman; Torben Palshof
[The course of cancer in health care--time for a time out?].
Ugeskrift for laeger 2011;173(24):1708.
2009: Lise Pedersen; Torben Palshof
[Pharmaceutical treatment of cancer-associated fatigue--a survey of a Cochrane review].
Ugeskrift for laeger 2009;171(39):2830-3.
2009: Torben Palshof
[...and the winner is...].
Ugeskrift for laeger 2009;171(25):2083.
2009: Jan Mainz; Anne-Marie Hansen; Torben Palshof; Paul D Bartels
National quality measurement using clinical indicators: the Danish National Indicator Project.
Journal of surgical oncology 2009;99(8):500-4.
2009: Erik Jakobsen; Torben Palshof; Kell Osterlind; Hans K Pilegaard
Data from a national lung cancer registry contributes to improve outcome and quality of surgery: Danish results.
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery 2009;35(2):348-52; discussion 352.
2008: Louise Brøndt Hartlev; Charlotte Bøje Rotbøl; Henrik Bluhme; Torben Palshof; Michael Rehling
[Monitoring renal function in patients treated with cytostatics].
Ugeskrift for laeger 2008;170(45):3664-7.
2008: M Sorensen; Ulrik Lassen; Torben Palshof; Britta Bjerregaard Jensen; Jørgen Johansen; Peter B Jensen; Seppo Langer
Topotecan and cisplatin in combination with concurrent twice-daily chemoradiation in limited disease small cell lung cancer-a Danish Oncological Lung Cancer Group (DOLG) phase II trial.
Lung cancer (Amsterdam, Netherlands) 2008;60(2):252-8.
2006: Marianne Bjerager; Torben Palshof; Ronald Dahl; Peter Vedsted; Frede Olesen
Delay in diagnosis of lung cancer in general practice.
The British journal of general practice : the journal of the Royal College of General Practitioners 2006;56(532):863-8.
2006: Karin Rasmussen; Hans H Madsen; Finn Rasmussen; Torben R Rasmussen; Ulrik Baandrup; Hans K Pilegaard; Ulrik Pedersen; Torben Palshof; Michael Rehling
The value of HRCT and Tc-depreotide in the evaluation of pulmonary lesions.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2006;1(4):296-301.
2006: Marianne Bjerager; Torben Palshof; Ronald Dahl; Frede Olesen
[General practitioners' attitudes towards the diagnosis of lung cancer and the diagnostic organisation].
Ugeskrift for laeger 2006;168(14):1443-7.
2003: Julie Damgaard Nielsen; Torben Palshof; Jan Mainz; Anders Bonde Jensen; Frede Olesen
Randomised controlled trial of a shared care programme for newly referred cancer patients: bridging the gap between general practice and hospital.
Quality & safety in health care 2003;12(4):263-72.
2002: Torben Palshof; Erik Jakobsen; Kell Østerlind
[Quality assurance and clinical databases].
Ugeskrift for laeger 2002;164(46):5407; author reply 5407.
2002: Gitte Olesen; Hanne Tønder; Torben Palshof; Peter Hokland
Peripheral blood accessory cells modulate committed colony-forming units but not 5-week cobblestone-area-forming cell outgrowth from CD34+ cells.
European journal of haematology 2002;68(2):65-72.
2002: Lise Pedersen; Anders Bonde Jensen; Bent Enig; Peter Vejby Hansen; Jørn Herrstedt; Niels Viggo Jensen; Nina Keldsen; Torben Palshof
[Palliative medicine education].
Ugeskrift for laeger 2002;164(4):500-2.
2001: Jan Maxwell Nørgaard; S T Langkjer; Torben Palshof; Bent Pedersen; Peter Hokland
Pretreatment leukaemia cell drug resistance is correlated to clinical outcome in acute myeloid leukaemia.
European journal of haematology 2001;66(3):160-7.
1999: Julie Damgaard Nielsen; Torben Palshof; Frede Olesen
[Cross-sectorial cooperation regarding cancer patients in a recently started care program. Ideas and themes based on focus group interviews with general practitioners and oncologists].
Ugeskrift for laeger 1999;161(14):2074-8.
1999: Jan Maxwell Nørgaard; P D Jensen; Knud Bendix; Niels Clausen; Torben Palshof
Relevance of in vitro leukaemia cell survival to short- and long term clinical outcome in AML.
Leukemia & lymphoma 1999;32(3-4):327-37.
1998: Jan Maxwell Nørgaard; A Bukh; S T Langkjer; Niels Clausen; Torben Palshof; Peter Hokland
MDR1 gene expression and drug resistance of AML cells.
British journal of haematology 1998;100(3):534-40.
1997: Gitte Olesen; M K Yilmaz; Torben Palshof; J K Møller; Niels Anker Peterslund
[Preventive strategies against infections in autologous bone marrow transplantation].
Ugeskrift for laeger 1997;159(10):1438-42.
1996: Jan Maxwell Nørgaard; S T Langkjer; Torben Palshof; Niels Clausen; B Pedersen; Peter Hokland
Relation of blast cell survival and proliferation to chemotherapy resistance in AML.
British journal of haematology 1996;93(4):888-97.
1993: Jan Maxwell Nørgaard; S T Langkjer; J Ellegaard; Torben Palshof; Niels Clausen; Peter Hokland
Synergistic and antagonistic effects of myeloid growth factors on in vitro cellular killing by cytotoxic drugs.
Leukemia research 1993;17(8):689-94.